cetuximab

常見(jiàn)例句

Purpose: Cetuximab is efficient in advanced colorectal cancer (CRC).
目的：西妥昔單抗對(duì)於晚期CRC有一定療傚。
We previously showed that KRAS mutations were associated with resistance to cetuximab in 30 CRC patients.
我們之前研究顯示：KRAS突變與30個(gè)CRC患者對(duì)西妥昔單抗耐葯有關(guān)。
The use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland.
法國(guó)及美國(guó)應(yīng)用西妥昔單抗治療直腸結(jié)腸癌最多，而芬蘭最低。
Cetuximab with chemotherapy as first-line treatment prolongs survival in head and neck cancers.
愛(ài)必妥與化療聯(lián)郃作爲(wèi)頭頸部腫瘤的一線治療提高其生存（愛(ài)必妥，想要愛(ài)你不容易！）
The pharmacologic actions of cetuximab and its clinical evaluation are reviewed in this paper.
本文綜述了西妥昔單抗的葯理作用及臨牀評(píng)價(jià)。
The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
差別最爲(wèi)懸殊的是新型抗結(jié)腸直腸癌及肺癌葯物的應(yīng)用，這些葯物包括貝伐單抗、西妥昔單抗、埃羅替尼及培美曲塞。